- Home
- GYRE vs TRIN Comparison
GYRE vs TRIN Comparison
Compare GYRE & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- TRIN
- Stock Information
- Founded
- GYRE 2002
- TRIN 2007
- Country
- GYRE United States
- TRIN United States
- Employees
- GYRE N/A
- TRIN N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- TRIN Finance/Investors Services
- Sector
- GYRE Health Care
- TRIN Finance
- Exchange
- GYRE Nasdaq
- TRIN Nasdaq
- Market Cap
- GYRE 897.1M
- TRIN 912.3M
- IPO Year
- GYRE N/A
- TRIN 2021
- Fundamental
- Price
- GYRE $9.07
- TRIN $14.56
- Analyst Decision
- GYRE
- TRIN Hold
- Analyst Count
- GYRE 0
- TRIN 3
- Target Price
- GYRE N/A
- TRIN $14.83
- AVG Volume (30 Days)
- GYRE 332.9K
- TRIN 484.4K
- Earning Date
- GYRE 05-09-2025
- TRIN 05-07-2025
- Dividend Yield
- GYRE N/A
- TRIN 14.00%
- EPS Growth
- GYRE N/A
- TRIN 37.77
- EPS
- GYRE 0.02
- TRIN 2.19
- Revenue
- GYRE $100,643,000.00
- TRIN $240,010,000.00
- Revenue This Year
- GYRE $22.01
- TRIN $24.43
- Revenue Next Year
- GYRE $88.14
- TRIN $6.17
- P/E Ratio
- GYRE $120.95
- TRIN $6.66
- Revenue Growth
- GYRE N/A
- TRIN 30.65
- 52 Week Low
- GYRE $6.11
- TRIN $12.50
- 52 Week High
- GYRE $19.00
- TRIN $16.82
- Technical
- Relative Strength Index (RSI)
- GYRE 45.78
- TRIN 49.02
- Support Level
- GYRE $9.26
- TRIN $14.28
- Resistance Level
- GYRE $11.61
- TRIN $14.78
- Average True Range (ATR)
- GYRE 1.09
- TRIN 0.22
- MACD
- GYRE -0.21
- TRIN 0.01
- Stochastic Oscillator
- GYRE 28.12
- TRIN 36.35
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.